Legal & General Group
PBYI icon

Legal & General Group’s Puma Biotechnology PBYI Stock Holding History

Legal & General Group’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$35K Buy
4,317
+753
+21% +$5.51K ﹤0.01% 2896
2026
Q1 		$22.8K Hold
3,564
– – ﹤0.01% 2918
2025
Q4 		$21.2K Hold
3,564
– – ﹤0.01% 3002
2025
Q3 		$18.9K Hold
3,564
– – ﹤0.01% 3062
2025
Q2 		$12.2K Sell
3,564
-348
-9% -$1.11K ﹤0.01% 3211
2025
Q1 		$11.6K Hold
3,912
– – ﹤0.01% 3126
2024
Q4 		$11.9K Hold
3,912
– – ﹤0.01% 3216
2024
Q3 		$9.97K Hold
3,912
– – ﹤0.01% 3274
2024
Q2 		$12.6K Buy
+3,912
New +$17.2K ﹤0.01% 3227
2022
Q2 		– Sell
-3,554
Closed -$10K – 3620
2022
Q1 		$10K Hold
3,554
– – ﹤0.01% 3406
2021
Q4 		$11K Sell
3,554
-8,458
-70% -$36.7K ﹤0.01% 3442
2021
Q3 		$84K Buy
12,012
+5,967
+99% +$44.7K ﹤0.01% 2885
2021
Q2 		$56K Hold
6,045
– – ﹤0.01% 2917
2021
Q1 		$59K Sell
6,045
-158
-3% -$1.76K ﹤0.01% 2768
2020
Q4 		$64K Hold
6,203
– – ﹤0.01% 2731
2020
Q3 		$62K Sell
6,203
-1,478
-19% -$15.1K ﹤0.01% 2619
2020
Q2 		$80K Buy
7,681
+97
+1% +$1K ﹤0.01% 2593
2020
Q1 		$64K Sell
7,584
-1,361
-15% -$13.2K ﹤0.01% 2527
2019
Q4 		$78K Buy
8,945
+1,172
+15% +$9.7K ﹤0.01% 2674
2019
Q3 		$84K Sell
7,773
-7,939
-51% -$85.7K ﹤0.01% 2574
2019
Q2 		$200K Buy
15,712
+1,055
+7% +$24.3K ﹤0.01% 2349
2019
Q1 		$569K Hold
14,657
– – ﹤0.01% 2129
2018
Q4 		$299K Buy
14,657
+4,676
+47% +$140K ﹤0.01% 2222
2018
Q3 		$458K Sell
9,981
-245
-2% -$11.8K ﹤0.01% 2161
2018
Q2 		$605K Sell
10,226
-518
-5% -$30K ﹤0.01% 2062
2018
Q1 		$731K Sell
10,744
-1,944
-15% -$146K ﹤0.01% 2012
2017
Q4 		$1.26M Buy
12,688
+823
+7% +$92.1K ﹤0.01% 1810
2017
Q3 		$1.41M Buy
11,865
+1,375
+13% +$128K ﹤0.01% 1726
2017
Q2 		$918K Buy
10,490
+1,193
+13% +$66.7K ﹤0.01% 1855
2017
Q1 		$346K Buy
9,297
+249
+3% +$9.09K ﹤0.01% 2115
2016
Q4 		$277K Buy
9,048
+3,085
+52% +$133K ﹤0.01% 2131
2016
Q3 		$382K Sell
5,963
-179
-3% -$9.05K ﹤0.01% 1829
2016
Q2 		$183K Buy
6,142
+3,608
+142% +$113K ﹤0.01% 1810
2016
Q1 		$75K Buy
2,534
+1,282
+102% +$57.9K ﹤0.01% 2229
2015
Q4 		$98K Sell
1,252
-11,890
-90% -$933K ﹤0.01% 2087
2015
Q3 		$990K Buy
13,142
+5,351
+69% +$506K ﹤0.01% 1119
2015
Q2 		$910K Buy
7,791
+3,675
+89% +$666K ﹤0.01% 1166
2015
Q1 		$967K Buy
4,116
+681
+20% +$146K ﹤0.01% 1123
2014
Q4 		$652K Sell
3,435
-149
-4% -$33.1K ﹤0.01% 1188
2014
Q3 		$876K Buy
+3,584
New +$736K ﹤0.01% 1075

Other funds holding PBYI

ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Legal & General Group's PBYI Position: Q2 2026 in Review

Legal & General Group increased its Puma Biotechnology (PBYI) stake by 21% in Q2 2026, buying an estimated $5.51K and bringing the position to 4,317 shares worth $35K. The position accounts for ﹤0.01% of the portfolio, ranked #2896.

Legal & General Group first reported a position in PBYI in Q3 2014 and has held it in 40 quarters since. The position peaked at $1.41M in Q3 2017. 160 funds tracked by Wall St. Rank hold PBYI as of Q2 2026.

  • Legal & General Group held 4,317 shares of Puma Biotechnology worth $35K as of Q2 2026.
  • Legal & General Group bought 753 Puma Biotechnology shares in Q2 2026, an estimated $5.51K.
  • Puma Biotechnology made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #2896 holding.
  • Legal & General Group first reported a position in Puma Biotechnology in Q3 2014 and has held it in 40 quarters since.
  • Legal & General Group's Puma Biotechnology position peaked at $1.41M in Q3 2017.
  • 160 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.